Benign Prostatic Hyperplasia Therapeutics Market Expected to Hit $ 20,097 Million by 2025, Growing at a CAGR of 8.1%
Benign prostatic hyperplasia (BPH) is a medical condition in which a male’s prostate gland size increases abnormally. This condition results in problems to start urination, weak urine stream, inability to empty the urinary bladder, and enhanced urine frequency usually at night. BPH therapeutics are drugs categorized into three different classes namely, alpha blocker, 5-alpha reductase inhibitor, and phosphodiesterase-5 inhibitor. These drugs relax the smooth bladder muscles or shrink the abnormal prostate growth to alleviate the BHP symptoms. The relaxation of the muscles of the bladder loosens the prostates grip on the urethra facilitating urine to flow more freely. Whereas, the shrinkage of the size of the prostate reduces the pressure exerted by the prostate on the urethra, resulting in free flow of urine.
Download PDF Report Sample @ https://www.alliedmarketresearch.com/request-sample/4708
Increasing prevalence of benign prostatic hyperplasia, rising global geriatric population, and soaring awareness related to urological disorders and prostate cancer across the world are the factors that drive the global benign prostatic hyperplasia therapeutics market growth. However, higher adoption rate of minimally-invasive surgical therapies instead of BPH therapeutics is expected to impede the market growth. Conversely, high market potential in the untapped emerging economies and presence of several pipeline products are expected to provide many opportunities during the forecast period.
The utilization rate of alpha blockers is high, owing to high availability of these products characterized by a higher success rate and lesser side effects. However, the 5-alpha reductase inhibitor segment is expected to grow at a high CAGR during the forecast period.
The mono drug therapy segment is the largest segment in the global benign prostatic hyperplasia therapeutics market, expanding at a moderate CAGR during the forecast period. On the other hand, the combination drug therapy segment is anticipated to record a high CAGR during the forecast period.
Make an Enquiry before Buy @ https://www.alliedmarketresearch.com/purchase-enquiry/4708
Key findings of the Benign Prostatic Hyperplasia Therapeutics Market:
• The phosphodiesterase-5 inhibitor segment accounted for nearly one-sixth share of the global benign prostatic hyperplasia therapeutics market in 2017.
• The mono drug therapy segment is expected to grow at a CAGR of 7.6% from 2018 to 2025.
• Europe accounted for around one-third share of the global market in 2017.
• LAMEA is expected to provide lucrative market growth opportunities and grow at a CAGR of 9.6% from 2018 to 2025.
North America was the leading revenue contributor to the global benign prostatic hyperplasia therapeutics market in 2017 and is expected to dominate the market during the forecast period. This is attributed to the early approval of BPH drugs and high adoption of drugs in this region. However, Asia-Pacific is expected to grow at the highest CAGR during the forecast period, owing to increase in affordability, surge in healthcare expenditure, and rise in awareness towards safe BPH drugs.
Access Full Summery @ https://www.alliedmarketresearch.com/benign-prostatic-hyperplasia-therapeutics-market
5933 NE Win Sivers Drive
#205, Portland, OR 97220
USA/Canada (Toll Free):
+1-800-792-5285, +1-503-894-6022, +1-503-446-1141
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Portland, Oregon. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions.” AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domain.
This release was published on openPR.
Permanent link to this press release:
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Benign Prostatic Hyperplasia Therapeutics Market Expected to Hit $ 20,097 Million by 2025, Growing at a CAGR of 8.1% here
News-ID: 1770580 • Views: 497
More Releases from Allied Market Research
Turbocharger Market Share, Generating Revenue Of $24.23 Million By 2027 At a CAG …
op 10 leading companies in the global turbocharger market are analyzed in the report along with their business overview, operations, financial analysis, SWOT profile and turbocharger products and services. The key players operating in the global turbocharger industry include BorgWarner Inc. Continental AG, Cummins Inc., EATON Corporation, Honeywell International Corporation, IHI Corporation, Mitsubishi Heavy Industries, Precision Turbo & Engine, Rotomaster International and Turbo Dynamics Ltd Latest news and industry developments
Commercial Satellite Imaging Market (Updated Research Report) Growth Analysis An …
The global commercial satellite imaging market was estimated at $2.24 billion in 2018 and is expected to reach $5.25 billion by 2026, growing at a CAGR of 11.2% from 2019-2026. The report offers a detailed analysis of the drivers & opportunities, top investment pockets, top winning strategies, market size & estimations, competitive scenario, and wavering market trends. Download Sample Report: https://www.alliedmarketresearch.com/request-sample/1751 Increasing adoption of location-based service (LBS) and rising application of
Rolling Stock Market Price, Revenue, Gross Profit, Interview Record, Business Di …
Rolling Stock Market by Product Type (Locomotives, Rapid Transit (DMU, EMU, Light Rail, Metro) Wagons, Coaches), Locomotive Propulsion (Diesel and Electric), Application (Passenger & Freight), Components: Global Opportunity Analysis and Industry Forecast, 2019-2026.” According to the report, the global rolling stock industry garnered $58.60 billion in 2018, and is expected to reach $73.8 billion by 2026, growing at a CAGR of 2.9% from 2019 to 2026. Access Full Summary @ https://www.alliedmarketresearch.com/rolling-stock-market
Safety Relay Market Growth Projections and Performance Forecast Analysis for the …
Allied Market Research published a new report, titled, "Safety Relay Market by Type (Single-Function Safety Relays and Modular & Configurable Safety Relays), Contact (Normally Closed, Time Open (NCTO), Normally Closed, Time Closed (NCTC), Normally Open, Time Open (NOTO), Normally Open, Time Closed (NOTC)) and End User (Automotive, Energy & Power, Manufacturing, Pharmaceutical, Construction, Semiconductors, and Oil & Gas): Global Opportunity Analysis and Industry Forecast, 2020–2026." The research report offers an in-depth
More Releases for Benign
Global Benign Prostatic Hyperplasia Treatment Devices Market Outlook 2018-2025 K …
A detailed market study on "Global Benign Prostatic Hyperplasia (BPH) Treatment Devices Market" examines the performance of the Benign Prostatic Hyperplasia (BPH) Treatment Devices market. It encloses an in-depth Research of the Benign Prostatic Hyperplasia (BPH) Treatment Devices market state and the competitive landscape globally. This report analyzes the potential of Benign Prostatic Hyperplasia (BPH) Treatment Devices market in the present and the future prospects from various angles in detail. The
Benign Positional Vertigo Market by Type - Benign, Paroxysmal, Positional and Ve …
The Global Benign Positional Vertigo Market is growing at the CAGR of ~4.0% during the forecast period and expected to reach US$ 797.3 million by 2023. Benign Positional Vertigo Market Segments: Worldwide Benign Positional Vertigo Market has been segmented on the basis of type which Benign, Paroxysmal, Positional, Vertigo, and others. On the basis of diagnosis, it is segmented into Electroencephalogram (EEG), Electronystagmography (ENG), Head CT, Head MRI, Hearing test, Magnetic resonance
Cold Plasma Market Benign Rate by 2025
Global Cold Plasma Market: Snapshot Cold plasma, additionally called non-warm plasma or non-balance plasma, is a sort of plasma—ordinarily known as the fourth condition of issue—which has gas particles show at direct temperature and electrons at moderately high temperatures. The properties of plasma have been widely looked into in the course of recent decades and an extensive number of front line utilizations of cold plasma innovation has exuded. Cold plasma isn't in
Benign Prostatic Hyperplasia Therapeutics Market Epidemiology Analysis, Therapy, …
The global benign prostatic hyperplasia therapeutics market is expected to witness significant growth, as increased number of effective treatments are available for cancer. Increasing awareness regarding various cancer treatment drugs, technological advancements, and growing demand for safe and effective medications are acting as the major growth drivers for the benign prostatic hyperplasia therapeutics market. Globally, regulatory bodies are adding to the growth of the market with provision of funding, grants
Benign Prostatic Hyperplasia and Prostatitis Devicebased Treatments Market
ReportsWorldwide has announced the addition of a new report title Benign Prostatic Hyperplasia and Prostatitis Devicebased Treatments Market to its growing collection of premium market research reports. This analysis includes a discussion of products, competitors, market forecasts, and opportunities in the global market for BPH and prostatitis treatment devices. Topics Covered Include: An overview of device-based and pharmacological therapies for BPH and prostatitis. Global and country/region-specific market forecasts, including forecasts by product segment. Competitive analyses
Benign Prostatic Hyperplasia Therapeutics Development Pipeline Overview for H1 2 …
2017 Benign Prostatic Hyperplasia pipeline market report of on global industry analysis and opportunity assessment H1 report provides comprehensive information on the therapeutics under development for Benign Prostatic Hyperplasia (Male Health), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. Get Discount on this Research Report at http://www.reportsnreports.com/contacts/discount.aspx?name=1010746 Benign Prostatic Hyperplasia (BPH) is a non-cancerous enlargement of the prostate, a